SGLT2 inhibitors have been studied in combination therapy with a range of antihyperglycemic agents. Check your math, here, with our 6 "add-on" questions.
SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.
© Tetiana Yurchenko/Shutterstock.com